Next generation Y analogue for treatment of obesity

Over 1 in 4 adults in the UK are obese, and a new injected drug called Y3394 aims to suppress appetite by mimicking a natural gut hormone. This matters because current obesity treatments are expensive, limited in supply, or difficult to adjust for individual patients. Peptide YY (PYY) is a hormone the bowel releases after eating, which naturally reduces appetite. The researchers have engineered Y3394 as a synthetic version of PYY that can be injected under the skin. In this early-stage project, they will test the drug’s safety in healthy volunteers, measure how long it stays in the bloodstream, and make preliminary checks on whether it causes weight loss. If the drug proves safe and effective, it could become a cheaper, adjustable treatment for obesity—a disease that affects 300 million people globally and causes an estimated 3 million premature deaths each year. A successful Y3394 would give clinicians a new tool to help patients lose weight by directly targeting the body’s own appetite-control system, without the need for surgery or complex regimens.